First-Year Trajectories of Medical Cannabis Use Among Adults Taking Opioids for Chronic Pain: An Observational Cohort Study

Pain Medicine ◽  
2021 ◽  
Author(s):  
Jonathan Ross ◽  
Deepika E Slawek ◽  
Chenshu Zhang ◽  
Joanna L Starrels ◽  
Frances R Levin ◽  
...  

Abstract Objective To describe first-year trajectories of medical cannabis use and identify characteristics associated with patterns of use in a cohort of adults using opioids for chronic pain. Design Latent class trajectory analysis of a prospective cohort study using data on the 14-day frequency of medical cannabis use. Setting A large academic medical center and four medical cannabis dispensaries in the New York City metropolitan area. Subjects Adults with chronic pain using opioids and newly certified for medical cannabis in New York between 2018 and 2020. Methods Using latent class trajectory analysis, we identified clusters of participants based on the 14-day frequency of medical cannabis use. We used logistic regression to determine factors associated with cluster membership, including sociodemographic characteristics, pain, substance use, and mental health symptoms. Results Among 99 participants, the mean age was 53 years; 62% were women, and 52% were White. We identified three clusters of medical cannabis use: infrequent use (n = 30, mean use = 1.5 days/14-day period), occasional use (n = 28, mean = 5.7 days/14-day period), and frequent use (n = 41, mean = 12.1 days/14-day period). Within clusters, use patterns did not vary significantly over 52 weeks. Differences were observed in two sociodemographic variables: Frequent (vs infrequent) use was associated with non-Hispanic White race/ethnicity (adjusted odds ratio 4.54, 95% confidence interval 1.49–14.29), while occasional (vs infrequent) use was associated with employment (adjusted odds ratio 13.84, 95% confidence interval 1.21–158.74). Conclusions Three clusters of medical cannabis use patterns emerged and were stable over time. Results suggest that structural factors related to race/ethnicity and employment may be major drivers of medical cannabis use, even among adults certified for its use.

Author(s):  
Matthias Pierce ◽  
Sally McManus ◽  
Holly Hope ◽  
Matthew Hotopf ◽  
Tamsin Ford ◽  
...  

2021 ◽  
pp. 100460
Author(s):  
Erin M. Anderson Goodell ◽  
Courtney Nordeck ◽  
Patrick H. Finan ◽  
Ryan Vandrey ◽  
Kelly E. Dunn ◽  
...  

2020 ◽  
Author(s):  
Nicholas Lintzeris ◽  
Llewellyn Mills ◽  
Anastasia Suraev ◽  
Maria Bravo ◽  
Thomas Arkell ◽  
...  

Abstract Background: In 2016 the Australian federal government passed legislation enabling a range of cannabis-based products to be prescribed to patients by registered healthcare professionals. An online survey conducted immediately prior to these legislative changes found that the vast majority of respondents at the time were illicitly sourcing cannabis plant matter, smoking was the preferred route of administration, and mental health, chronic pain, and sleep conditions were the most frequently cited reasons for medical cannabis use. This manuscript reports the results of a follow-up survey conducted in 2018-2019, the Cannabis As Medicine Survey (CAMS-18). The goal of this second questionnaire was to examine patterns of use and consumer perspectives regarding medical cannabis use in Australia, two years after the introduction of legal access pathways. Methods: Anonymous online cross-sectional survey with convenience sample, recruited mainly through online media between September 2018 and March 2019. Participants were adults (18 years or over) residing in Australia who reported using a cannabis product for self-identified therapeutic reasons during the preceding 12 months. The survey measured consumer characteristics; indications and patterns of medical cannabis use; routes and frequency of administration; perceived benefits and harms; experiences and preferred models of access to medical cannabis. Results: Data were available for 1388 respondents. The main categories of condition being treated with medical cannabis were pain (36.4%), mental health (32.8%), sleep (9.2%), neurological (5.2%) and cancer (3.8%). Respondents reported using medical cannabis on 15.8 (11.2) days in the past 28, by inhaled (71.4%) or oral (26.5%) routes and spending AUD$82.27 ($101.27) per week. There were high levels of self-reported effectiveness, but also high rates of side effects. There was uncertainty regarding the composition of illicit cannabinoid products and concerns regarding their possible contamination. Few respondents (2.7%) had accessed legally prescribed medical cannabis, with the main perceived barriers being cost, disinterest from the medical profession, and stigma regarding cannabis use. Conclusions: Chronic pain, mental health and sleep remain the main clinical conditions for which consumers report using medical cannabis. Despite two years of legal availability, most consumers in Australia reported accessing illicit cannabis products, with uncertainty regarding the quality or composition of cannabis products.


2021 ◽  
Vol 82 (6) ◽  
pp. 792-800
Author(s):  
Noel A. Vest ◽  
Fernanda S. Rossi ◽  
Mark Ilgen ◽  
Keith Humphreys ◽  
Christine Timko

2009 ◽  
Vol 24 (4) ◽  
pp. 411-429 ◽  
Author(s):  
David C. Geary ◽  
Drew H. Bailey ◽  
Andrew Littlefield ◽  
Phillip Wood ◽  
Mary K. Hoard ◽  
...  

2017 ◽  
Vol 40 (10) ◽  
pp. 1452-1468 ◽  
Author(s):  
Chen X. Chen ◽  
Susan Ofner ◽  
Giorgos Bakoyannis ◽  
Kristine L. Kwekkeboom ◽  
Janet S. Carpenter

Dysmenorrhea is highly prevalent and may increase women’s risk for developing other chronic pain conditions. Although it is highly variable, symptom-based dysmenorrhea phenotypes have not been identified. The aims of the study were to identify symptom-based dysmenorrhea phenotypes and examine their relationships with demographic and clinical characteristics. In a cross-sectional study, 762 women with dysmenorrhea rated severity of 14 dysmenorrhea-related symptoms. Using latent class analysis, we identified three distinctive phenotypes. Women in the “mild localized pain” phenotype ( n = 202, 26.51%) had mild abdominal cramps and dull abdominal pain/discomfort. Women in the “severe localized pain” phenotype ( n = 412, 54.07%) had severe abdominal cramps. Women in the “multiple severe symptoms” phenotype ( n = 148, 19.42%) had severe pain at multiple locations and multiple gastrointestinal symptoms. Race, ethnicity, age, and comorbid chronic pain conditions were significantly associated with phenotypes. Identification of these symptom-based phenotypes provides a foundation for research examining genotype–phenotype associations, etiologic mechanisms, and/or variability in treatment responses.


2020 ◽  
Vol 21 (5-6) ◽  
pp. 570-581 ◽  
Author(s):  
Kevin F. Boehnke ◽  
J. Ryan Scott ◽  
Evangelos Litinas ◽  
Suzanne Sisley ◽  
David A. Williams ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document